Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 1L | First line |
| 5-FU | Fluorouracil (5-fluorouracil) |
| ADCC | Antibody-dependent cellular cytotoxicity |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| aPTT | Activated partial thromboplastin time |
| ASCO | American Society of Clinical Oncology |
| AST | Aspartate aminotransferase |
| AUC | Area under the curve |
| AUC0–168h | Area under the plasma concentration versus time curve from 0 to 168 hours |
| BIA | Budget impact analysis |
| BICR | Blinded independent central review |
| BLA | Biologics License Application |
| BRAF | B-Raf proto-oncogene |
| BTD | Breakthrough Therapy Designation |
| CBR | Clinical benefit rate |
| CD4 | Cluster of differentiation 4 |
| CD8 | Cluster of differentiation 8 |
| CDKN2A | Cyclin-dependent kinase inhibitor 2A |
| CEA | Cost-effectiveness analysis |
| CF | Cisplatin and fluorouracil |
| CHO | Chinese hamster ovary |
| CHUM | Centre hospitalier de l'Université de Montréal |
| CI | Confidence interval |
| CL | Clearance |
| CLIA | Clinical Laboratory Improvement Amendments |
| Cmax | Maximal concentration |
| cORR | Confirmed objective response rate |
| COST | Comprehensive Score for Financial Toxicity |
| CP | Cisplatin and paclitaxel |
| CPS | Combined positive score |
| CR | Complete response |
| CrCl | Creatinine clearance |
| CXCL10 | C-X-C motif chemokine ligand 10 |
| CXCL9 | C-X-C motif chemokine ligand 9 |
| D1 | Day 1 |
| DCR | Disease control rate |
| DDS | Dose determination set |
| DFS | Disease-free survival |
| DLT | Dose-limiting toxicity |
| DNA | Deoxyribonucleic acid |
| DOR | Duration of response |
| EBV | Epstein-Barr virus |
| ECOG | Eastern Cooperative Oncology Group |
| EE | Efficacy evaluable |
| EES | Efficacy-evaluable set |
| EGF | Epidermal growth factor |
| EGFR | Epidermal growth factor receptor |
| EMT | Epithelial-mesenchymal transition |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EQ-5D-3L | EuroQol 5-dimension 3-level instrument |
| ERBB2 | Erb-b2 receptor tyrosine kinase 2 |
| ESMO | European Society for Medical Oncology |
| EU | European Union |
| EU5 | France, Germany, Italy, Spain, and the United Kingdom |
| EXTREME | Cetuximab plus platinum and fluorouracil |
| FAS | Full analysis set |
| FAT1 | FAT atypical cadherin 1 |
| FDA | Food and Drug Administration |
| FDQ | Financial Distress Questionnaire |
| FGFR1 | Fibroblast growth factor receptor 1 |
| FICERA | Ficerafusp alfa |
| FT | Financial toxicity |
| FU | Fluorouracil |
| G4S | Glycine-glycine-glycine-glycine-serine peptide linker unit |
| GHS | Global health status |
| GLOBOCAN | Global Cancer Incidence, Mortality and Prevalence |
| HBV | Hepatitis B virus |
| HCRU | Health care resource utilization |
| HCV | Hepatitis C virus |
| hEGFR | Human epidermal growth factor receptor |
| HEK | Human embryonic kidney |
| HER2 | Human epidermal growth factor receptor 2 |
| HFX | Hyperfractionated radiation therapy |
| HIV | Human immunodeficiency virus |
| HN | Head and neck |
| HNC | Head and neck cancer |
| HNSCC | Head and neck squamous cell carcinoma |
| HPV | Human papillomavirus |
| HPV16 | Human papillomavirus type 16 |
| HR | Hazard ratio |
| HR-HPV | High-risk human papillomavirus |
| HRQoL | Health-related quality of life |
| HSCT | Hematopoietic stem cell transplantation |
| HSUV | Health state utility value |
| ICER | Incremental cost-effectiveness ratio |
| ICF | Informed consent form |
| ICI | Immune checkpoint inhibitor |
| IDMC | Independent data monitoring committee |
| IFN-γ | Interferon gamma |
| IgG1 | Immunoglobulin G1 |
| IHC | Immunohistochemistry |
| IL-10 | Interleukin 10 |
| IMRT | Intensity-modulated radiotherapy |
| INHB | Incremental net health benefit |
| INMB | Incremental net monetary benefit |
| INN | International Nonproprietary Name |
| IO | Immuno-oncology |
| IQR | Interquartile range |
| iRECIST | Response Evaluation Criteria in Solid Tumors for immune-based therapeutics |
| IRR | Infusion-related reaction |
| ISH | In situ hybridization |
| iTreg | Inducible regulatory T cell |
| ITT | Intention-to-treat |
| IV | Intravenous |
| LA | Locally advanced |
| LC | Local control |
| mAb | Monoclonal antibody |
| MDT | Multidisciplinary team |
| mHNC | Metastatic head and neck cancer |
| mo | Month |
| mOS | Median overall survival |
| mPFS | Median progression-free survival |
| MSD | Merck Sharp & Dohme |
| MTD | Maximum tolerated dose |
| MTX | Methotrexate |
| N/A | Not applicable |
| NA | Not applicable |
| NCCN | National Comprehensive Cancer Network |
| NCI | National Cancer Institute |
| NE | Not estimable |
| NJ | New Jersey |
| NM | Not mature |
| NOTCH1 | Notch receptor 1 |
| NR | Not reached |
| NS | Not significant |
| NSCLC | Non-small cell lung cancer |
| NSD1 | Nuclear receptor binding SET domain protein 1 |
| OBD | Optimal biological dose |
| OOP | Out-of-pocket |
| OPC | Oropharyngeal cancer |
| OPSCC | Oropharyngeal squamous cell carcinoma |
| OR | Odds ratio |
| ORR | Objective response rate |
| OS | Overall survival |
| PCR | Polymerase chain reaction |
| PD | Progressed disease |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death-ligand 1 |
| PD-L2 | Programmed death-ligand 2 |
| pembro | Pembrolizumab |
| PFS | Progression-free survival |
| PFS2 | Progression-free survival 2 |
| PK | Pharmacokinetics |
| PO | Oral administration |
| PPPM | Per patient per month |
| PPT | Post-platinum therapy |
| PR | Partial response |
| PS | Performance status |
| pSMAD2 | Phosphorylated SMAD family member 2 |
| PT | Prothrombin time |
| pts | Patients |
| Q2W | Every 2 weeks |
| Q3W | Every 3 weeks |
| Q6W | Every 6 weeks |
| QALY | Quality-adjusted life-year |
| QLQ-C30 | Quality of Life Questionnaire Core 30 |
| QLQ-H&N35 | Quality of Life Questionnaire head and neck cancer-specific module, 35 questions |
| QoL | Quality of life |
| QW | Once weekly |
| R/M | Recurrent or metastatic |
| RAS | RAS family of proto-oncogenes |
| RD | Recommended dose |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| rHNC | Recurrent head and neck cancer |
| RNA | Ribonucleic acid |
| RT | Radiotherapy |
| RTOG | Radiation Therapy Oncology Group |
| rwOS | Real-world overall survival |
| rwToT | Real-world time on treatment |
| rwTTNT | Real-world time to next treatment |
| SA | Safety analysis |
| SAE | Serious adverse event |
| SBRT | Stereotactic body radiotherapy |
| SCAC | Squamous cell carcinoma of the anal canal |
| SCAI | Salvage chemotherapy after immunotherapy |
| SCC | Squamous cell carcinoma |
| SCCAC | Squamous cell carcinoma of the anal canal |
| SCCHN | Squamous cell carcinoma of the head and neck |
| SCT | Salvage chemotherapy |
| SD | Stable disease; standard deviation |
| SEER | Surveillance, Epidemiology, and End Results |
| SMAD4 | SMAD family member 4 |
| SPT | Second primary tumor |
| TEAE | Treatment-emergent adverse event |
| TGF-beta | Transforming growth factor beta |
| TGF-β | Transforming growth factor beta |
| TGFβRII | Transforming growth factor beta receptor II |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |
| TNF-α | Tumor necrosis factor alpha |
| TP53 | Tumor protein p53 |
| TPEx | Docetaxel, cisplatin, and cetuximab |
| TPS | Tumor proportion score |
| TRAE | Treatment-related adverse event |
| TSG | Tumor suppressor gene |
| TT | Time toxicity |
| TTD | Time to deterioration |
| TTR | Time to response |
| Tyr1068 | Tyrosine residue 1068 |
| UC | University of California |
| ULN | Upper limit of normal |
| UPMC | University of Pittsburgh Medical Center |
| US | United States |
| USA | United States of America |
| USC | University of Southern California |
| VEGF | Vascular endothelial growth factor |
| vs | Versus |
| WAC | Wholesale acquisition cost |
| WHO | World Health Organization |
| WOCBP | Women of childbearing potential |
| WS | Wait and see |
| WTP | Willingness-to-pay |